Nuestro interés es entender los mecanismos moleculares y celulares del desarrollo y progresión del cáncer. Específicamente como contribuye una proteína clave en esta enfermedad es el supresor de tumor p53, estamos enfocados en establecer modelos de estudio que nos permitan elucidar como las mutantes de p53 contribuyen a la progresión del cáncer. Además, estamos interesados en el estudio de compuestos que pueden funcionar como agentes quimio y/o radiosensibilizadores en la terapia del cáncer.

Publicaciones

1. Dominguez-Gomez G, Chavez-Blanco A, Medina-Franco JL, Saldivar-Gonzalez F, Flores-Torrontegui Y, Juarez M, Díaz-Chávez J, Gonzalez-Fierro A, Dueñas-González A. Ivermectin as an inhibitor of cancer stem‑like cells. Mol Med Rep. 2018;17(2):3397-3403. FI: 3.4.

2. Leon-Galicia I*, Diaz-Chavez J*, Albino-Sanchez ME, Garcia-Villa E, Bermudez-Cruz R, Garcia-Mena J, Herrera LA, García-Carranca A, Gariglio P. Resveratrol decreases Rad51 expression and sensitizes cisplatin‑resistant MCF‑7 breast cancer cells. Oncol Rep. 2018;39(6):3025-3033. FI: 4.2.
3. Munguía-Moreno JA*, Díaz-Chavéz J*, García-Villa E, Albino-Sanchez ME, Mendoza-Villanueva D, Ocadiz-Delgado R, Bonilla-Delgado J, Marín-Flores A, Cortés-Malagón EM, Alvarez-Rios E, Hidalgo-Miranda A, Üren A, Çelik H, Lambert PF, Gariglio P. Early synergistic interactions between the HPV16‑E7 oncoprotein and 17β-oestradiol for repressing the expression of Granzyme B in a cervical cancer model. Int J Oncol. 2018;53(2):579-591. FI: 5.2.

4. Román-Rosales AA, García-Villa E, Herrera LA, Gariglio P, Díaz-Chávez J*. Mutant p53 gain of function induces HER2 over-expression in cancer cells. BMC Cancer. 2018;18(1):709. FI: 3.8.

5. Hernandez-Valencia J, Garcia-Villa E, Arenas-Hernandez A, Garcia-Mena J, Diaz-Chavez J*, Gariglio P. Induction of p53 Phosphorylation at Serine 20 by Resveratrol Is Required to Activate p53 Target Genes, Restoring Apoptosis in MCF-7 Cells Resistant to Cisplatin. Nutrients. 2018;10(9). FI: 5.9.

6. Gallardo-Alvarado LN, Tusié-Luna MT, Tussié-Luna MI, Díaz-Chávez J, Segura YX, Bargallo-Rocha E, Villarreal C, Herrera-Montalvo LA, Herrera-Medina EM, Cantu-de Leon DF. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population. BMC Cancer. 2019;19(1):118. FI: 3.8.

7. Hernández-Juárez J, Vargas-Sierra O, Herrera LA, Cantú De León D, Fernández-Retana J, Pérez-Plasencia C, López-Camarillo C, Gariglio P, Díaz-Chávez J*. Sodium-coupled monocarboxylate transporter is a target of epigenetic repression in cervical cancer. Int J Oncol. 2019;54(5):1613-1624. FI: 5.2.

8. Gómez-Peñaloza C, Serrano-Arévalo ML, Villegas-González LF, Flores-Hernández L, Lino-Silva LS, Ruiz-García EB, Diaz-Chávez J. Addition of analysis of KRAS mutation or immunohistochemistry with MUC1 and carcinoembryonic antigen improves the diagnostic performance of fine needle aspiration cytology for the diagnosis of pancreatic carcinoma. Cytopathology. 2019;30(5):485-491. FI: 1.3.

9. Dominguez-Gomez G, Cortez-Pedroza D, Chavez-Blanco A, Taja-Chayeb L, Hidalgo-Miranda A, Cedro-Tanda A, Beltran-Anaya F, Diaz-Chavez J, Schcolnik-Cabrera A, Gonzalez-Fierro A, Dueñas-Gonzalez A. Growth inhibition and transcriptional effects of ribavirin in lymphoma. Oncol Rep. 2019;42(3):1248-1256. FI: 4.2.

10. Schcolnik-Cabrera A, Dominguez-Gómez G, Chávez-Blanco A, Ramírez-Yautentzi M, Morales-Bárcenas R, Díaz-Chávez J, Taja-Chayeb L, Dueñas-González A. A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells. Oncol Lett. 2019 Dec;18(6):6909-6916. FI: 2.9.

11. Contreras-Ochoa CO, López-Arellano ME, Roblero-Bartolon G, Díaz-Chávez J, Moreno-Banda GL, Reyna-Figueroa J, Munguía-Moreno JA, Madrid-Marina V, Lagunas-Martínez A. Molecular mechanisms of cell death induced in glioblastoma by experimental and antineoplastic drugs: New and old drugs induce apoptosis in glioblastoma. Hum Exp Toxicol. 2020;39(4):464-476. FI: 2.8.

12. Pagaza-Straffon C, Marchat LA, Herrera L, Díaz-Chávez J, Avante MG, Rodríguez YP, Arreola MC, López-Camarillo C. Evaluation of a panel of tumor-associated antigens in breast cancer. Cancer Biomark. 2020;27(2):207-211. FI: 3.1.

13. Andonegui-Elguera MA, Alfaro-Mora Y, Cáceres-Gutiérrez R, Caro-Sánchez CHS, Herrera LA, Díaz-Chávez J*. An Overview of Vasculogenic Mimicry in Breast Cancer. Front Oncol. 2020;10:220. FI: 4.7.

14. Juarez M, Schcolnik-Cabrera A, Dominguez-Gomez G, Chavez-Blanco A, Diaz-Chavez J, Duenas-Gonzalez A. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Cancer Chemother Pharmacol. 2020;85(6):1153-1163. FI: 3.0.

15. Bandala-Jacques A, Hernández-Cruz IA, Castro-Hernández C, Díaz-Chávez J, Arriaga-Canon C, Barquet-Muñoz SA, Prada-Ortega DG, Cantú-de León D, Herrera LA. Prognostic Significance of the MAD1L1 1673 G: A Polymorphism in Ovarian Adenocarcinomas. Rev Invest Clin. 2020;73(3): 372-379. FI: 0.47.

16. Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, Juarez M, Lai D, Hua S, Tovar AR, Diaz-Chavez J, Duenas-Gonzalez A. The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells. Oncol Lett. 2020;20(3):3053-3060. FI: 2.9.

17. Landero-Huerta DA, Vigueras-Villaseñor RM, Yokoyama-Rebollar E, García-Andrade F, Rojas-Castañeda JC, Herrera-Montalvo LA, Díaz-Chávez J, Pérez-Añorve IX, Aréchaga-Ocampo E, Chávez-Saldaña MD. Cryptorchidism and Testicular Tumor: Comprehensive Analysis of Common Clinical Features and Search of SNVs in the KIT and AR Genes. Front Cell Dev Biol. 2020 Aug 7;8:762. FI: 5.5.

18. Muñiz-Hernández S, Velázquez-Fernández JB, Díaz-Chávez J, Mondragón-Fonseca O, Mayén-Lobo Y, Ortega A, López-López M, Arrieta O. STRA6 Polymorphisms Are Associated With EGFR Mutations in Locally-Advanced and Metastatic Non-Small Cell Lung Cancer Patients. Front Oncol. 2020;10:579561. FI: 4.7.

19. Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, Juarez M, Vargas-Castillo A, Ponce-Toledo RI, Lai D, Hua S, Tovar AR, Torres N, Perez-Montiel D, Diaz-Chavez J, Duenas-Gonzalez A. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy. Sci Rep. 2021;11(1):5222. FI: 4.6.

20. Prada D, Baccarelli AA, Terry MB, Valdéz L, Cabrera P, Just A, Kloog I, Caro H, García-Cuellar C, Sánchez-Pérez Y, Cruz R, Diaz-Chávez J, Cortés C, Pérez D, Meneses-García A, Cantú-de-León D, Herrera LA, Bargalló E. Long-term PM2.5 exposure before diagnosis is associated with worse outcome in breast cancer. Breast Cancer Res Treat. 2021;188(2):525-533. FI: 3.8.

21. Landero-Huerta DA, Vigueras-Villaseñor RM, Taja-Chayeb L, García-Andrade F, Aréchaga-Ocampo E, Yokoyama-Rebollar E, Díaz-Chávez J, Herrera LA, Chávez-Saldaña MD. Analysis of the CAG tract length in the Androgen Receptor gene in Mexican patients with nonsyndromic cryptorchidism. J Pediatr Endocrinol Metab. 2021; 34(7):843-849. FI: 1.4.

22. Contreras-Espinosa L, Alcaraz N, De La Rosa-Velázquez IA, Díaz-Chávez J, Cabrera-Galeana P, Vega RR, Reynoso-Noveron N, Maldonado-Martínez HA, González-Barrios R, Montiel-Manríquez R, Bautista-Sánchez D, Castro-Hernández C, Álvarez-Gómez RM, Jiménez-Trejo F, Tapia-Rodríguez M, García-Gordillo J, Pérez-Rosas A, Bargallo-Rocha E, Arriaga-Canon C, Herrera LA. Transcriptome Analysis Identifies GATA3-AS1 as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. J Mol Diagn. 2021;S1525-1578(21)00238-5. FI: 4.1.

23. Alfaro-Mora Y, Domínguez-Gómez G, Cáceres-Gutiérrez RE, Tolentino-García L, Herrera LA, Castro-Hernández C, Bermúdez-Cruz RM, Díaz-Chávez J*. MPS1 is involved in the HPV16-E7-mediated centrosomes amplification. Cell Div. 2021 Nov 4;16(1):6. FI: 2.3.

24. Madrigal T, Hernández-Monge J, Herrera LA, González-De la Rosa CH, Domínguez-Gómez G, Candelaria M, Luna-Maldonado F, Calderón González KG, Díaz-Chávez J*. Regulation of miRNAs Expression by Mutant p53 Gain of Function in Cancer. J.Front Cell Dev Biol. 2021;9:695723. FI: 5.5.

25. Rodríguez-Bautista R, Caro-Sánchez CH, Cabrera-Galeana P, Alanis-Funes GJ, Gutierrez-Millán E, Ávila-Ríos S, Matías-Florentino M, Reyes-Terán G, Díaz-Chávez J, Villarreal-Garza C, Hernández-Pedro NY, Ortega-Gómez A, Lara-Mejía L, Rangel-Escareño C, Arrieta O. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers (Basel). 2021;13(24):6256. FI: 5.2.

26. Luna-Maldonado F, Andonegui-Elguera MA, Díaz-Chávez J*, Herrera LA. Mitotic and DNA Damage Response Proteins: Maintaining the Genome Stability and Working for the Common Good. Front Cell Dev Biol. 2021;9:700162. FI: 5.5.

27. Cáceres-Gutiérrez RE, Andonegui MA, Oliva-Rico DA, González-Barrios R, Luna F, Arriaga-Canon C, López-Saavedra A, Prada D, Castro C, Parmentier L, Díaz-Chávez J, Alfaro-Mora Y, Navarro-Delgado EI, Fabian-Morales E, Tran B, Shetty J, Zhao Y, Alcaraz N, De la Rosa C, Reyes JL, Hédouin S, Hubé F, Francastel C, Herrera LA. Proteasome inhibition alters mitotic progression through the upregulation of centromeric α-satellite RNAs. FEBS J. 2022;289(7):1858-1875. FI: 5.4.

28. Cáceres-Gutiérrez RE, Alfaro-Mora Y, Andonegui MA, Díaz-Chávez J*, Herrera LA. The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways. Front Cell Dev Biol. 2022;10:751367. FI: 5.5.

29. González-Barrios R, Alcaraz N, Montalvo-Casimiro M, Cervera A, Arriaga-Canon C, Munguia-Garza P, Hinojosa-Ugarte D, Sobrevilla-Moreno N, Torres-Arciga K, Mendoza-Perez J, Diaz-Chavez J, Cortes-González CC, Castro-Hernández C, Martínez-Cedillo J, Scavuzzo A, Pérez-Montiel D, Jiménez-Ríos MA, Herrera LA. Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based Therapy. Cancers (Basel). 2022;14(9):2065. FI: 5.2.

30. Andonegui-Elguera MA, Cáceres-Gutiérrez RE, López-Saavedra A, Cisneros-Soberanis F, Justo-Garrido M, Díaz-Chávez J*, Herrera LA. The Roles of Histone Post-Translational Modifications in the Formation and Function of a Mitotic Chromosome. Int J Mol Sci. 2022;23(15):8704. FI: 5.6.

31. Del Castillo Falconi VM, Torres-Arciga K, Matus-Ortega G, Díaz-Chávez J*, Herrera LA. DNA Methyltransferases: From Evolution to Clinical Applications. Int J Mol Sci. 2022;23(16):8994. FI: 5.6.

32. García-Andrade F, Vigueras-Villaseñor RM, Chávez-Saldaña MD, Rojas-Castañeda JC, Bahena-Ocampo IU, Aréchaga-Ocampo E, Díaz-Chávez J, Landero-Huerta DA. The Role of microRNAs in the Gonocyte Theory as Target of Malignancy: Looking for Potential Diagnostic Biomarkers. Int J Mol Sci. 2022;23(18):10526. FI: 5.6.

33. Díaz-Chávez J*, Gutiérrez-Hernández O, Taja-Chayeb L, Gutiérrez-Chavarría S, Avilés-Salas A, Candelaria M. ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma. Cancers (Basel). 2022;14(19):4650. FI: 5.2.

34. Del Castillo Falconi VM, Díaz-Chávez J*, Torres-Arciga K, Luna-Maldonado F, Gudiño-Gomez AA, Pedroza-Torres A, Castro-Hernández C, Cantú de León D, Herrera LA. Expression of DNA Methyltransferase 3B Isoforms Is Associated with DNA Satellite 2 Hypomethylation and Clinical Prognosis in Advanced High-Grade Serous Ovarian Carcinoma. Int J Mol Sci. 2022 Oct 22;23(21):12759. FI: 5.6.

35. Andonegui-Elguera MA, Cáceres-Gutiérrez RE, Oliva-Rico D, Díaz-Chávez J*, Herrera LA. LncRNAs-associated to genomic instability: A barrier to cancer therapy effectiveness. Front Genet. 2022;13:984329. FI: 3.7.

36. Pérez-Montiel MD, Cerrato-Izaguirre D, Sánchez-Pérez Y, Diaz-Chavez J, Cortés-González CC, Rubio JA, Jiménez-Ríos MA, Herrera LA, Scavuzzo A, Meneses-García A, Hernández-Martínez R, Vaca-Paniagua F, Ramírez A, Orozco A, Cantú-de-León D, Prada D. Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion. Int J Mol Sci. 2023;24(2):1092. FI: 5.6.

37. García-Andrade F, Vigueras-Villaseñor RM, Chávez-Saldaña MD, Rojas-Castañeda JC, Bahena-Ocampo IU, Aréchaga-Ocampo E, Flores-Fortis M, Díaz-Chávez J, Herrera LA, Landero-Huerta DA. Molecular Characterization of Patients with Cryptorchidism: Preliminary Search for an Expression Profile Related to That of Testicular Germ-Cell Tumors. Diagnostics (Basel). 2023;13(18):3020. FI: 3.6.

Circuito de Posgrado, Ciudad Universitaria
Alcaldía Coyoacán, C.P. 04510, México, CDMX

55 5623 7006
mdcbq@posgrado.unam.mx